Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin

Sul Park; Jae Jin Jung; Goeng Bae Kim; Hyung Sik Yoon; Sang Hun Ko; Jae Ee Ko; Yeun Seun Lee

doi:10.4166/kjg.2010.55.5.340

Journal List > Korean J Gastroenterol > v.55(5) > 1006670

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park, Jung, Kim, Yoon, Ko, Ko, and Lee: Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin

Original Article

Korean J Gastroenterol 2010;55(5):340-343.

Published online: 21 February 2010

DOI: https://doi.org/10.4166/kjg.2010.55.5.340

Interstitial Lung Disease Associated with Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin

Sul Park, M.D., Jae Jin Jung, M.D., Goeng Bae Kim, M.D., Hyung Sik Yoon, M.D., Sang Hun Ko, M.D., Jae Ee Ko, M.D., Yeun Seun Lee, M.D.

Department of Internal Medicine, Sun General Hospital, Daejeon, Korea

Correspondence to: Yeun Sun Lee, M.D. Department of Internal Medicine, Sun General Hospital, 10-7, Mok-dong, Daejeon 301-725, Korea Tel: +82-42-220-8802, Fax: +82-42-252-6171 E-mail: cnu4169@hanmail.net

Received 2 December 2009 Accepted 23 December 2009

Abstract

Oxaliplatin with 5-fluorouracil plus leucovorin (FOLFOX) has become the standard treatment in patients with colorectal cancer. Among known toxicities induced by oxaliplatin, hematological, gastrointestinal and neurological toxicities are common. However, acute pulmonary toxicity associated with oxaliplatin is unusual. One case of interstitial lung disease associated with the FOLFOX protocol is reported here.

Keywords: Oxaliplatin, Colon cancer, Interstitial lung diseases

REFERENCES

1. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23–30.

2. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350:2343–2351.

3. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management and evaluation of chemotherapy- induced peripheral neuropathy. Semin Oncol. 2006; 33:15–49.

4. Jung KH, Kil SY, Choi IK, et al. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Int J Tuberc Lung Dis. 2006; 10:1181–1182.

5. Ruiz-Casado A, Garcí a MD, Racionero MA. Pulmonary toxicity of 5-fluorouracil and oxaliplatin. Clin Transl Oncol. 2006; 8:624.

6. Pasetto LM, Monfardini S. Is acute dyspnea related to oxaliplatin administration? World J Gastroenterol. 2006; 12:5907–5908.

7. Gagnadoux F, Roiron C, Carrie E, Monnier-Cholley L, Lebeau B. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. Am J Clin Oncol. 2002; 25:388–390.

8. Trisolini R, Lazzeri Agli L, Tassinari D, et al. Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J. 2001; 18:243–245.

9. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002; 1:227–235.

10. Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol. 2003; 15:2904–2911.

11. Yague XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colo-mer R. Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol. 2005; 7:515–517.

12. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15:460–466.

13. Kinnula VL, Vuorinen K, Ilumets H, Rytilä P, Myllä rniemi M. Thiol proteins, redox modulation and parenchymal lung disease. Curr Med Chem. 2007; 14:213–222.

14. Demedts M, Costabel U. ATS/ERS international multidis-ciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002; 19:794–796.

15. Wells AU. High-resolution computed tomography in the diagnosis of diffuse lung disease: a clinical perspective. Semin Respir Crit Care Med. 2003; 24:347–356.

16. Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clin Proc. 2007; 82:976–986.

17. Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 178:372–378.

Fig. 1.

Chest x-ray. (A) On admission, chest x-ray showed lung without specific infiltration. (B) After 9 ^th cycle of chemotherapy, retic-ulonodular infiltration was observed on both lower lung field.

Fig. 2.

Chest CT scan of both lower lung. (A) On admission, CT scan showed no specific infiltration. (B) After 9 ^th cycle of chemotherapy, reciculo- nodular pattern with ground-glass opacity and honeycomb change were observed.

TOOLS

Similar articles